Silexion Therapeutics Corp., a clinical-stage biotechnology company, has announced promising results from a preclinical study showcasing the significant efficacy of their RNA interference therapy, SIL204, in human lung cancer cell lines. The study demonstrated dose-dependent inhibition in cells with KRAS G12D mutations, supporting SIL204's potential as a versatile therapeutic for lung cancer. The company is also conducting additional studies on a previously untested KRAS mutation, with results expected to be released in the near future. Silexion plans to initiate a Phase 2/3 clinical trial in the second quarter of 2026 to further investigate SIL204 for the treatment of KRAS-driven solid tumor cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.